PDUFA Waivers, Reductions, and Refunds for Fixed- Combinations and Single-Entity Versions of Previously Approved Antiretrovirals under PEPFAR
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
August 3, 2023
August 4, 2023
6d0b93d6-4d11-41b1-815d-d6970112dcdd
Related Documents
Establishing Impurity Specifications for Antibiotics
Guidance DocumentApril 20, 2026Center for Drug Evaluation and Research
Alcoholism: Developing Drugs for Treatment
Guidance DocumentFebruary 12, 2015Center for Drug Evaluation and Research
Prescription Drug User Fee Act Waivers for Fixed-Combination Antiretroviral Drugs for the President’s Emergency Plan for AIDS Relief: Draft Guidance for Industry
Guidance DocumentJune 7, 2018Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox